Latest news for Eros Media World (OTC:EMWPF) Stock

Eros Media World PLC is a film production and distribution company. It distributes its film content across multiplex chains and stand-alone theatres and broadcasts television content via tie-ups with channels such as ZEE TV and Star TV. The company also has a digital presence through its website; www.erosnow.com and an independent channel on Youtube. Geographically, it has a presence in India, North America, Europe and the Rest of the world. The company's primary revenue streams are derived from three channels: theatrical, television syndication and digital and ancillary.

EROS MEDIA WORLD PLC A by Eros Media World PLC

Eros Media World PLC

<ul>
<li>NVDA</li>
<li>TSLA</li>
<li>CRWD</li>
<li>WAY</li>
<li>DJT</li>
<li>TSM</li>
<li>QQQ</li>
<li>AMD</li>
<li>LOT</li>
<li>AI</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

CRWD

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of July 22 2024 (Via Swaggy Stocks)

WIIM

Shares of Nvidia are trading higher following a report suggesting the company is preparing a version of its AI chips for the Chinese market. Additionally, Piper Sandler maintained an Overweight rating and raised its price target from $120 to $140.

Monday, Hepion Pharmaceuticals Inc (NASDAQ:&nbsp;HEPA) entered into a definitive merger agreement with Pharma Two B Ltd., a late-clinical stage private Israeli company developing P2B001, a combination product candidate in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39880821/pharma-two-b-announces-plans-to-go-public-via-merger-with-hepion-pharmaceuticals-inc-and-concurren" rel="noreferrer noopener">development for Parkinson&#8217;s Disease</a>.
The merger is valued at an estimated pro-forma implied equity value of approximately $58.5 million.
Hepion will merge into and become an indirectly wholly-owned subsidiary of Pharma Two B.
The combined company will continue to operate under the &#8220;Pharma Two B&#8221; name. Pharma Two B has agreed to file a registration statement with the SEC to register the ordinary shares proposed to be issued to Hepion&#8217;s equity holders in the acquisition. It will also apply to list its ordinary shares on Nasdaq under the ticker symbol &#8220;PHTB.&#8221;
&#8220;P2B001 offers a novel, easy-to-use therapeutic approach, that is designed to address the unmet need for an effective, safe, once-daily, no titration required treatment with a lower incidence of excessive daytime sleepiness—a common side effect of currently available dopamine agonist treatments in Parkinson&#8217;s disease patients&#8221; said Dan Teleman, Chief Executive Officer of Pharma Two B.
&#8220;Our company is in a stage that we believe meets the public market and investors&#8217; expectations. We are excited about Pharma Two B&#8217;s next growth phase, moving P2B001 towards an NDA submission targeted for the first half of 2026 and making this potential treatment available to patients,&#8221; he continued.
Hepion has also announced a private placement of $2.9 million non-convertible senior notes to qualified institutional investors.
Pharma Two B has entered into a securities purchase agreement for an $11.5 million private placement of ordinary shares and accompanying Series A warrants and Series B warrants.
In April, Hepion Pharmaceuticals began wind-down activities in its ASCEND-NASH Trial while continuing to explore strategic alternatives, as previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/g38342739/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial" rel="noreferrer noopener">announced in December 2023</a>.
Price Action: HEPA stock is up 1.96% at $1.04 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39881151/johnson-johnson-faces-legal-hurdle-in-talc-lawsuit-battle" target="_blank" rel="noreferrer noopener">Johnson &amp; Johnson Faces Legal Hurdle In Talc Lawsuit Battle</a>.</li>
</ul>

Biotech

Equities

News

Health Care

Movers

General

HEPA

Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
<ul>
<li>Goldman Sachs cut the price target for Lennar Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) from $180 to $174. Goldman Sachs analyst Susan Maklari downgraded the stock from Buy to Neutral. Lennar shares gained 0.5% to close at $170.94 on Friday. <a href="https://www.benzinga.com/quote/LEN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler increased the price target for NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) from $120 to $140. Piper Sandler analyst Harsh Kumar maintained an Overweight rating. NVIDIA shares fell 2.6% to close at $117.93 on Friday. <a href="https://www.benzinga.com/quote/ITCI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush cut the price target for Chuy&#8217;s Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHUY#NASDAQ">CHUY</a>) from $38 to $37.5. Wedbush analyst Nick Setyan downgraded the stock from Outperform to Neutral. Chuy&#8217;s shares fell 0.7% to close at $37.08 on Friday. <a href="https://www.benzinga.com/quote/CHUY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities decreased Comerica Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) price target from $55 to $53. Truist Securities analyst Brandon King downgraded the stock from Buy to Hold. Comerica shares fell 10.5% to close at $50.42 on Friday. <a href="https://www.benzinga.com/quote/CMA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities boosted the price target for Redwire Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) from $6 to $8. B. Riley Securities analyst Mike Crawford downgraded the stock from Buy to Neutral. Redwire shares fell 0.9% to close at $6.98 on Friday. <a href="https://www.benzinga.com/quote/RDW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel raised International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) price target from $95 to $115. Stifel analyst Mark Astrachan upgraded the stock from Hold to Buy. International Flavors shares fell 1% to close at $95.67 on Friday. <a href="https://www.benzinga.com/quote/IFF/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Henry Schein, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) price target from $81 to $92. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. Henry Schein shares fell 0.5% to close at $70.34 on Friday. <a href="https://www.benzinga.com/quote/HSIC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) price target from $75 to $70. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. Alaska Air shares gained 1.8% to close at $37.93 on Friday. <a href="https://www.benzinga.com/quote/ALK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank cut Domino&#8217;s Pizza, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) price target from $580 to $500. Deutsche Bank analyst Lauren Silberman maintained a Buy rating. Domino&#8217;s shares fell 1.2% to close at $404.17 on Friday. <a href="https://www.benzinga.com/quote/DPZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan increased Abercrombie &amp; Fitch Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) price target from $167 to $194. JP Morgan analyst Matthew Boss upgraded the stock from Neutral to Overweight. Abercrombie &amp; Fitch shares gained 1% to close at $158.51 on Friday. <a href="https://www.benzinga.com/quote/ANF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39876945/s-p-500-logs-worst-weekly-decline-since-april-investor-optimism-falls-further">S&amp;P 500 Logs Worst Weekly Decline Since April; Investor Optimism Falls Further</a></li>
</ul>

Price Target

Markets

Analyst Ratings

CHUY

HSIC

ITCI

NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Piper Sandler analyst Scott Siefers maintains Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) with a Underweight and raises the price target from $11.5 to $13.5.

HBAN

Piper Sandler Maintains Underweight on Huntington Bancshares, Raises Price Target to $13.5

Barclays analyst Jared Shaw maintains Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) with a Overweight and raises the price target from $86 to $92.

Barclays Maintains Overweight on Western Alliance, Raises Price Target to $92

Barclays analyst Eric Beaumont maintains WEC Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) with a Underweight and raises the price target from $78 to $80.

Barclays Maintains Underweight on WEC Energy Group, Raises Price Target to $80

Piper Sandler analyst Luke Lemoine maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Overweight and lowers the price target from $46 to $40.

Piper Sandler Maintains Overweight on Halliburton, Lowers Price Target to $40

By&nbsp;Lance Roberts
Over the last few years, a handful of&nbsp;&ldquo;Mega-Capitalization&rdquo;&nbsp;(mega-market capitalization)&nbsp;stocks have dominated market returns. The question is whether that dominance will continue and if the same companies remain the leaders. It is an interesting question. The number of publicly traded companies continues to decline, as shown in the following chart from<a href="https://www.apolloacademy.com/significant-decline-in-the-number-of-publicly-listed-companies/" rel="noreferrer noopener" target="_blank">&nbsp;Apollo.</a>
<img alt="Number of publicly listed U.S. companies" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-59-1024x576.png" style="height:351px; width:624px" />
This decline has many reasons, including mergers and acquisitions, bankruptcy, leveraged buyouts, and private equity. For example, Twitter&nbsp;(now X)&nbsp;was once a publicly traded company before Elon Musk acquired it and took it private. Unsurprisingly, with fewer publicly traded companies, there are fewer opportunities as market capital increases. Such is particularly the case for large institutions that must deploy large amounts of capital over short periods. With nearly 40% of the companies in the Russell 2000 index currently non-profitable, the choices are limited even further.
<img alt="Percentage of companies in the Russell 2000 that are non-profitable." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-60-1024x576.png" style="height:351px; width:624px" />
However, this period&rsquo;s concentration of market capitalization into a few names is not unique. In the 1960s and 1970s, it was the&nbsp;&ldquo;Nifty 50.&rdquo; Then, in the late 90s, it was the &ldquo;Dot.com&rdquo;&nbsp;darlings like Cisco Systems. Today, it is anything related to&nbsp;&ldquo;artificial Intelligence.&rdquo;
<img alt="Stock market concentration over time. " src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-58.png" style="height:391px; width:624px" />
As shown, the leaders of the past are not today&rsquo;s leaders. Notably, Nvidia&nbsp;(NVDA)&nbsp;will get added to the list of the largest&nbsp;&ldquo;mega-cap&rdquo;&nbsp;companies for the first time in 2024.
<img alt="Stocks with the largest market capitalization over time." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-57.png" style="height:368px; width:624px" />
However, investors must decide whether Microsoft, Apple, Google, and Amazon will remain the leaders over the coming decade. Just as AT&amp;T and GM were once the darlings of Wall Street, today&rsquo;s Technology shares may become relics of the past.
<h3 id="h-earnings-growth">Earnings Growth</h3>
One primary determinant in answering that question is earnings growth. As should be obvious, investors are willing to pay higher prices when corporate earnings are growing.
<img alt="Earnings growth vs. the annual rate of change in the market." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/SP500-Earnings-vs-Ann-ROC-in-SP-500.png" style="height:332px; width:624px" />
The problem is that in 2023, all the earnings growth came from the&nbsp;index&rsquo;s top-7&nbsp;&ldquo;mega-capitalization&rdquo;&nbsp;stocks. The S&amp;P 500 would have had negative earnings growth excluding those seven stocks. Such would have likely resulted in a more disappointing market outcome. Notably, while analysts are optimistic that earnings growth for the bottom 493 stocks will accelerate into the end of 2024, with economic data slowing, those hopes will likely be disappointed.
<img alt="Earnings growth top 7 companies versus the bottom 493." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-61.png" style="height:369px; width:624px" />
Over the next decade, companies like Microsoft, Apple, and Alphabet will face the challenge of growing revenues fast enough to keep earnings growth rates elevated. Given that Nvidia is a relatively young company in a fast-growing industry, it has been able to increase revenues sharply to support higher valuation multiples.
<img alt="Nivida Revenue" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-62.png" style="height:314px; width:624px" />
However, Apple, a very mature company, cannot grow revenues at such a high rate. Such is simply because of the law of large numbers. I have included a 5-year annualized growth rate of revenues to illustrate the issue better.
<img alt="Apple Revenue" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-63.png" style="height:312px; width:624px" />
That is where the Wall Street axiom&nbsp;&ldquo;Trees don&rsquo;t grow to the sky&rdquo;&nbsp;comes from.&nbsp;&nbsp;
In investing, it describes the danger of maturing companies with a high growth rate. In some cases, a company with an exponential growth rate will achieve a high valuation based on the unrealistic expectation that growth will continue at the same pace as the company becomes larger. For example, if a company has $10 billion in revenue and a 200% growth rate, it&rsquo;s easy to think it will achieve 100s of billions in revenue within a few short years. 
However, the larger a company becomes, the more difficult it becomes to achieve a high growth rate. For example, a firm with a 1% market share might quickly achieve 2%. However, when a firm has an 80% market share, doubling sales requires growing the market or entering new markets where it isn&rsquo;t as strong. Firms also tend to become less efficient and innovative as they grow due to diseconomies of scale.
For this reason, many of today&rsquo;s top market capitalization-weighted stocks may not be the same in a decade. Just as AT&amp;T is a relic of yesterday&rsquo;s&nbsp;&ldquo;new technology,&rdquo;&nbsp;such may be true with Apple a few years from now when no one needs a&nbsp;&ldquo;smartphone&rdquo;&nbsp;anymore.
<h3 id="h-passive-investing-s-impact">Passive Investing&rsquo;s Impact</h3>
Over the last two decades, the rise of passive investing has been another interesting change in the financial markets.&nbsp;<a href="https://realinvestmentadvice.com/its-not-2000-but-there-are-similarities/" rel="noreferrer noopener" target="_blank">As discussed previously</a>, the top-10&nbsp;&ldquo;mega-capitalization&rdquo;&nbsp;stocks in the S&amp;P 500 index comprise more than 1/3rd of the index.&nbsp;In other words, a 1% gain in the top 10 stocks is the same as a 1% gain in the bottom 90%.&nbsp;As investors buy shares of a passive ETF, the ETF must purchase the shares of all the underlying companies. Given the massive inflows into ETFs over the last year and subsequent inflows into the top 10 stocks, the mirage of market stability is not surprising.
<img alt="Market cap weighting of top 10 stocks in the index" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/Top-10-Stocks-Market-Cap-Weighting-060124.png" style="height:415px; width:624px" />
Unsurprisingly, the forced feeding of dollars into the largest weighted stocks makes market performance appear more robust than it is. That is also why the S&amp;P 500 market-capitalization weighted index has outperformed the equal-weighted index over the last few years.
<img alt="Two year performance of the market-cap weighted index vs. the equal weight." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/Market-Cap-Vs-Eq-Wgt-Rel-Performance.png" style="height:350px; width:624px" />
Investors often overlook this double-edged sword. For example, let&rsquo;s assume that Tesla was 5% in the S&amp;P 500 index before Nvidia entered the top 10. As Nvida&rsquo;s rapid share price increased its market capitalization, Tesla&rsquo;s was reduced as its stock price fell. Therefore, all index funds, passive fund managers, portfolio managers, etc., had to increase their weightings in Nvidia and reduce their ownership in Tesla.
<img alt="Market capitalization of Nvidia vs Tesla." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-64-1024x421.png" style="height:257px; width:624px" />
In the future, whatever the next generation of companies garners Wall Street&rsquo;s favor, the current leaders could fall out of the top 10 as the&nbsp;&ldquo;passive&rdquo;&nbsp;flows require additional selling of today&rsquo;s leaders to buy more of tomorrow&rsquo;s.
<h3 id="h-share-buybacks">Share Buybacks</h3>
Lastly, corporate share buybacks, expected to approach $1 trillion and exceed that in 2024, could weigh on current leadership. That is because the largest companies with the cash to execute large multi-billion dollar programs, like Apple, Microsoft, Alphabet, and Nvidia, dominate buybacks. For example, Apple alone will account for over 10% of 2024 buybacks.
<img alt="Annual Share Buyback Executions" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-65.png" style="height:479px; width:624px" />
If you don&rsquo;t understand the importance of share buybacks in maintaining the largest companies&rsquo; current market dominance, here is some basic math.
<ul>
<li>Pensions and MF = (-$2.7 Trillion)</li>
<li>Households and Foreign = +$2.4 Trillion
<ul>
<li>Sub Total = (-$0.3 Trillion)</li>
</ul>
</li>
<li>Corporations (Buybacks) = $5.5 Trillion
<ul>
<li>Net Total = $5.2 Trillion</li>
</ul>
</li>
</ul>
In other words, since 2000, corporations have provided 100% of all the net equity buying.
<img alt="Net demand for U.S. Equities." src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-66.png" style="height:374px; width:624px" />
Therefore, it should be unsurprising that there is a high correlation between the ebbs and flows of corporate share buybacks and market performance.
<img alt="Annual Change in buybacks vs the market" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/SP500-vs-Share-buybacks-Ann-Pct-Chg-1024x542.png" style="height:330px; width:624px" />
Therefore, as long as corporations remain the top buyers of their shares, the current dominance of the&nbsp;&ldquo;Mega-caps&rdquo;&nbsp;will continue. Of course, there are reasons the current rate of corporate share repurchases will end.
<ul>
<li>Changes to the tax code</li>
<li>A ban on share repurchases (they were previously illegal due to their ability to manipulate markets)</li>
<li>A reversal of profitability, making share repurchases onerous.</li>
<li>Economic recession/credit event where corporations go on the defensive (i.e., 2000, 2008, 2022)</li>
</ul>
Whatever the reason, the eventual reversal of buyback programs could severely limit the current leader&rsquo;s market dominance.
I have no clue what event causes such a reversal or when. However, a reversal could undo mega-cap dominance since corporate share buybacks have provided all the net equity buying for the largest stocks.
<h2 id="h-conclusion">Conclusion</h2>
The current dominance of the largest &ldquo;Mega-capitalization&rdquo;&nbsp;companies is unsurprising. As noted, they make up the bulk of earnings growth and revenues of the S&amp;P 500 index, the largest purchasers of their shares. These are also the same companies in the middle of the current &ldquo;Artificial Intelligence&rdquo; revolution, as has been the case for the last decade.
However, given the speed at which technology and the economy rapidly change, such suggests that leaders of the last decade may not be the leaders of the next.
<img alt="Historical Market Bubbles" src="https://realinvestmentadvice.com/wp-content/uploads/2024/06/image-67.png" style="height:363px; width:624px" />
As investors, it is vital to understand the dynamics of each market cycle and invest accordingly. However, those buying stocks today at some of the most extreme valuations we have seen over the last century and expecting those shares to dominate over the next decade could be disappointed.
Many variables support the current secular bull market cycle. However, as has been the case throughout history, a myopic approach to investing has led to poor outcomes.
Invest accordingly.
Lance Roberts is a Chief Portfolio Strategist/Economist for&nbsp;<a href="https://realinvestmentadvice.com/investing/" target="_blank">RIA Advisors</a>. He is also the host of &ldquo;<a href="https://realinvestmentadvice.com/podcasts/" target="_blank">The Lance Roberts Podcast</a>&rdquo; and Chief Editor of the &ldquo;<a href="https://realinvestmentadvice.com/" target="_blank">Real Investment Advice</a>&rdquo; website and author of &ldquo;<a href="https://realinvestmentadvice.com/real-investment-daily/" target="_blank">Real Investment Daily</a>&rdquo; blog and &ldquo;Real Investment Report&ldquo;. Follow Lance on&nbsp;<a href="https://www.facebook.com/RealInvestmentAdvice/" target="_blank">Facebook</a>,&nbsp;<a href="https://twitter.com/LanceRoberts" target="_blank">Twitter</a>,&nbsp;<a href="https://www.linkedin.com/in/realinvestmentadvice/" target="_blank">Linked-In</a>&nbsp;and&nbsp;<a href="https://www.youtube.com/channel/UCXVMMgEidXlrTM1coedg70A" target="_blank">YouTube</a>

Tech

Can Mega-Capitalization Stocks Continue Their Dominance?

Monday, Addex Therapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) announced its partner Janssen Pharmaceuticals, Inc, a unit of Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), has discontinued the development of ADX71149 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39875937/addexs-partner-discontinues-adx71149-development-in-epilepsy" rel="noreferrer noopener">(JNJ-40411813) in epilepsy</a>.
The partnership between the two companies remains ongoing while the full data set from the Phase 2 study of ADX71149 (JNJ-40411813) as an adjunctive epilepsy treatment is analyzed.
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38493033/johnson-johnson-partnered-addex-therapeutics-epilepsy-candidate-fails-mid-stage-study-stock-tanks" rel="noreferrer noopener">added to standard of care</a>.
After the data, Addex Therapeutics stock tumbled almost 50%.
&#8220;Following the Phase 2 study results in epilepsy, this decision was anticipated. We have had an excellent working relationship with Janssen for twenty years and will continue to work diligently to complete the analysis of the full Phase 2 data set to elucidate all learnings from the study,&#8221; said Tim Dyer, CEO of Addex. &#8220;Once we have that information in hand, we anticipate a decision on the future of this asset.&#8221;
Price Action: ADXN stock is down 1.36% at $7.99 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/07/39864734/craze-for-ozempic-and-zepbound-for-weight-loss-leave-diabetic-patients-without-critical-glp-1-med" target="_blank" rel="noreferrer noopener">Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications</a>.</li>
</ul>

Large Cap

ADXN

After Disappointing Data, Johnson & Johnson Halts Developing Epilepsy Drug Candidate

NVNI

Nuvini Group Joins Russell Microcap Growth Index, Russell 3000E Index, Russell Microcap Growth Value Index, And Russell 3000E Value Index

Axcelis Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NYSE">ACLS</a>) short percent of float has risen 19.37% since its last report. The company recently reported that it has 2.19 million shares sold short, which is 9.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.6 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Axcelis Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721654122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Axcelis Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Axcelis Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Axcelis Technologies's peer group average for short interest as a percentage of float is 7.05%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

ACLS

How Is The Market Feeling About Axcelis Technologies?

ENPH

Enphase Energy shares are trading higher after Piper Sandler maintained a Neutral rating but raised its price target from $111 to $120.

Sprouts Farmers Market's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NYSE">SFM</a>) short percent of float has fallen 9.99% since its last report. The company recently reported that it has 9.72 million shares sold short, which is 15.32% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Sprouts Farmers Market Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721654117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Sprouts Farmers Market has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Sprouts Farmers Market's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Sprouts Farmers Market's peer group average for short interest as a percentage of float is 4.36%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(SFM) - Analyzing Sprouts Farmers Market's Short Interest

Federal Signal's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSS#NYSE">FSS</a>) short percent of float has risen 11.45% since its last report. The company recently reported that it has 637 thousand shares sold short, which is 1.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.89 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Federal Signal Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1721654112_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Federal Signal has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Federal Signal's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Federal Signal's peer group average for short interest as a percentage of float is 5.85%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Federal Signal?

Piper Sandler analyst Frank Schiraldi reiterates Cass Information Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASS#NASDAQ">CASS</a>) with a Overweight and lowers the price target from $47 to $44.

Reiteration

CASS

Piper Sandler Reiterates Overweight on Cass Information Sys, Lowers Price Target to $44

Barclays analyst Benjamin Budish maintains Carlyle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CG#NASDAQ">CG</a>) with a Overweight and raises the price target from $47 to $51.

Barclays Maintains Overweight on Carlyle Group, Raises Price Target to $51

Piper Sandler analyst Alexander Goldfarb maintains Alexander's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALX#NYSE">ALX</a>) with a Underweight and lowers the price target from $145 to $135.

Piper Sandler Maintains Underweight on Alexander's, Lowers Price Target to $135

VHAI

Vocodia Holdings Announces New Client MD Exam; Plans To Integrate Advanced AI Into Telemedicine Provider's Contact Center Operations Within 90 Days After Successful Pilot

Hong Kong is set to list the region&#8217;s first Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) futures inverse product on Tuesday.
What Happened: The CSOP Bitcoin Futures Daily (-1x) Inverse Product (7376.HK) will be traded on the Hong Kong Stock Exchange, marking a new milestone in the evolution of crypto-based financial instruments in the region, <a href="https://csop-pdf-bucket1.s3.ap-east-1.amazonaws.com/upload/pdf/875c3f10-0b14-4d53-9102-177b9eda7873.pdf">according</a> to a press release.
This innovative product aims to provide investment results that closely correspond to the one-time inverse daily performance of the S&amp;P Bitcoin Futures Index, before fees and expenses. 
It will utilize a futures-based replication strategy, investing directly in the spot month CME Bitcoin Futures and following a rolling strategy.
The launch comes at a time when Bitcoin&#8217;s volatility remains a significant factor in the crypto market. 
In 2023, Bitcoin&#8217;s volatility reached 38.3%, surpassing that of both crude oil and the Nasdaq 100. 
This high volatility, coupled with Bitcoin&#8217;s lack of intrinsic value, has created a market environment where both long and short positions can potentially yield significant returns.
Interestingly, the first quarter of 2024 saw global futures-based Bitcoin inverse products experience their highest quarterly inflow since the second quarter of 2023, totaling $79 million. 
As of the end of June 2024, Bitcoin CME futures recorded a record high in net short interest among leveraged funds, reaching approximately $5.7 billion.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39867522/trump-campaign-eyes-crypto-voters-what-vp-jd-vances-nomination-means-for-bitcoin">Trump Campaign Eyes Crypto Voters: What VP JD Vance&#8217;s Nomination Means For Bitcoin</a>
Why It Matters: The introduction of this inverse product provides investors with an opportunity to potentially profit from downward movements in Bitcoin futures prices without directly participating in the bitcoin futures market.
This could be particularly relevant given the potential impacts of the upcoming U.S. presidential election, supply dynamics and Federal Reserve monetary policy on Bitcoin prices.
The product will have a listing price of about HKD 7.8 per unit, with a trading lot of 100 and a management fee of 1.99%. It has reportedly received an initial investment of around 30 million US dollars.
This development underscores the growing sophistication of crypto-related financial products in Asia and highlights Hong Kong&#8217;s role as a key player in the region&#8217;s digital asset ecosystem. 
As the crypto market continues to evolve, products like these are likely to play an increasingly important role in investment strategies.
For those interested in exploring the implications of such products and the broader trends in the digital asset space, the upcoming Benzinga <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19 will provide a platform for in-depth discussions.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39866338/bitcoin-as-a-strategic-reserve-asset-for-the-us-expert-details-how-trump-could-make-it-hap">Bitcoin As A Strategic Reserve Asset For The US? Expert Details How Trump Could Make It Happen</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Eros Media World

News

Latest news for Eros Media World (OTC:EMWPF) Stock